Search Results
Your search for ,aLl matches 18302 pages
Showing 10551 - 10600AACR-NCI-EORTC: Colorectal Cancer Test Could Detect Early Cancer-Causing Genetic Biomarkers With High Degree of Sensitivity
An investigational test that screens for colorectal cancer could detect genetic mutations that are indicative of the disease with a high degree of sensitivity and specificity, according to results of a study presented by Powell et al at the AACR-NCI-EORTC International Conference on Molecular...
Gary Gilliland, MD, PhD, Testifies Before Congress on NIH Funding System
Gary Gilliland, MD, PhD, President and Director of Fred Hutchinson Cancer Research Center, recently delivered the following testimony and answered questions from members of the House Appropriations Subcommittee on Labor, Health and Human Services, Education, and Related Agencies. His remarks...
AACR-NCI-EORTC: Tipifarnib Shows Durable Antitumor Activity in HRAS-Mutant Head and Neck Cancer
Preliminary results from a phase II open-label trial of tipifarnib, a farnesyltransferase inhibitor, in patients with HRAS-mutant head and neck squamous cell carcinoma (HNSCC) were presented by Alan L. Ho, MD, PhD, of Memorial Sloan Kettering Cancer Center, at the AACR-NCI-EORTC International...
Combination Therapy for Docetaxel-Pretreated Metastatic Castration-Resistant Prostate Cancer
The phase III AFFINITY trial has shown no survival benefit with the addition of the antisense oligonucleotide custirsen to cabazitaxel (Jevtana)/prednisone in patients with metastatic prostate cancer previously treated with docetaxel. These findings were reported in The Lancet Oncology by Beer et...
Potential Treatment of Chordoma With PI3K Inhibitors
Patients with chordoma—a rare bone cancer of the skull and spine—could be helped by existing treatments, suggest scientists from the Wellcome Trust Sanger Institute, University College London Cancer Institute, and the Royal National Orthopaedic Hospital NHS Trust. In the largest...
Extended Aromatase Inhibitor Therapy After Sequential Endocrine Therapy
In the Dutch phase III DATA trial reported in The Lancet Oncology by Tjan-Heinjen et al, a nonsignificant disease-free survival advantage was found for 6 vs 3 years of adjuvant aromatase inhibitor therapy after 2 to 3 years of tamoxifen in hormone receptor–positive early breast cancer....
2017 ASCO Palliative Care: Yoga Can Be an Effective Supportive Therapy for People With Lung Cancer and Their Caregivers
In a feasibility trial of people with advanced lung cancer receiving radiation therapy and their caregivers, yoga was beneficial to both parties. These findings will be presented by Milbury et al at the upcoming 2017 Palliative and Supportive Care in Oncology Symposium in San Diego (Abstract 125). ...
2017 ASCO Palliative Care: People With Leukemia and Their Oncologists Have Vastly Different Perceptions of Prognosis
A study of 100 people with acute myeloid leukemia (AML) receiving chemotherapy found that patient and physician perceptions of treatment risk and the likelihood of a cure varied widely. Overall, patients tended to overestimate both the risk of dying due to treatment and the likelihood of a cure....
MAF Amplification and Outcomes With Adjuvant Zoledronic Acid in Early Breast Cancer
An analysis from the phase III AZURE trial has shown that MAF-negative status was associated with a benefit and MAF-positive status, with a detriment of adjuvant zoledronic acid in early breast cancer. The analysis was reported by Coleman et al in The Lancet Oncology. Study Details The current...
Long-Term Outcomes With BRAF and MEK Inhibition in BRAF V600–Mutant Metastatic Melanoma
As reported by Long et al in the Journal of Clinical Oncology, a 5-year landmark analysis of patients receiving dabrafenib (Tafinlar) and trametinib (Mekinist) for BRAF V600–mutant metastatic melanoma shows persistent overall and progression-free survival benefits. Study Details The...
Leading Lymphoma Clinician, Researcher, and Mentor, Oliver ‘Ollie’ Press, MD, PhD, Dies at 65
In 1988, 38-year-old Rita Lawrence found herself in a desperate situation. The lymphoma she’d been battling had recurred after 2 years of remission. She’d endured multiple rounds of tough chemotherapy, but it couldn’t stave off the swiftly growing tumors. When she learned of a radioimmunotherapy...
BE PREPARED TO ENCOURAGE HPV VACCINATION
“Human papillomavirus (HPV) vaccination coverage lags behind coverage for the other vaccines recommended for preteens,” according to the Centers for Disease Control and Prevention (CDC).1 A recent report about vaccination coverage in the United States among adolescents aged 13 to 17 found that...
2017 ASCO Palliative Care: Resilience Intervention Improves Quality of Life for Adolescents and Young Adults With Cancer
Although a cancer diagnosis is daunting at any age, adolescents and young adults (AYAs) with the disease often face unique challenges and are at risk for poor psychosocial outcomes than older patients. A randomized study investigating whether a brief, age-appropriate, skills-based intervention...
Register for December 1 FDA Workshop on Cardiovascular Toxicities in Immunotherapy Trials
THE U.S. FOOD & DRUG ADMINISTRATION (FDA) and the Oncology Center of Excellence (OCE) will host a complimentary public workshop, Assessment of Cardiovascular Toxicities in Immuno-Oncology Trials, on December 1. ASCO is supporting the workshop with the American College of Cardiology (ACC), the...
For Your Patients: ASCO Answers Managing Cancer-Related Pain Booklet
ASCO’S BOOKLET on Managing Cancer-Related Pain helps you work together with your patients to develop an individualized plan for pain management before they start treatment. Patients and their caregivers will learn about the importance of pain relief, including its causes, how it is diagnosed, and...
Quality Training Program Now Accepting Applications for 2018; Courses to Be Held in Miami and Northern Virginia
Applications are now being accepted for ASCO’s Quality Training Program (QTP), a comprehensive program designed to train oncology health-care providers to investigate and implement data-driven quality improvement, as well as manage clinical and nonclinical processes and outcomes. The program...
Recommend an Early-Career Oncologist for ASCO’s 2018 Health Policy Fellowship
APPLICATIONS ARE now being accepted for ASCO’s 2018 Health Policy Fellowship program. The Health Policy Fellowship aims to provide oncology fellows and early-career physicians with the necessary skills to shape cancer policy and to help increase the involvement of ASCO members in policy, advocacy,...
Documentary Film Takes a Walk on the Wild Side With Oncology Pioneers
Oncology luminaries. Thought leaders. The soul of chemotherapy. These are just a few of the phrases used to describe Emil Frei, MD, FASCO, Emil J Freireich, MD, FASCO, James F. Holland, MD, FASCO, Georges Mathé, MD, and their historic contributions to the world of oncology. Inspired by these...
Funding the Future of Cancer Research Led by Women Making an Impact
WOMEN WHO CONQUER CANCER (WWCC) funds the promising careers of the best and brightest women researchers through the Conquer Cancer Foundation’s Young Investigator Award (YIA) program. Thanks to the generosity of supporters, five awards were granted in 2017. Right now, gifts to the WWCC Endowment...
ASCO University Offers New Course Covering Resource-Stratified Guidelines
ASCO has created a series of clinical practice guidelines to benefit clinicians, public health leaders, and policymakers in all resource settings. These resource-stratified guidelines help medical professionals outline appropriate methods of treatment and care based on the level of health-care...
Effectiveness of Sentinel Lymph Node Biopsy in Patients With Newly Diagnosed Melanoma
Research presented at the 9th World Congress of Melanoma supports the updated guideline recommendation that sentinel lymph node biopsy be performed in more patients newly diagnosed with melanoma, as it has the potential to save lives due to the information the procedure provides. This biopsy can...
Axl Inhibitor BGB324 in Combination With Trametinib Plus Dabrafenib or Pembrolizumab in Advanced Melanoma
BerGenBio ASA announced that the randomized phase Ib/II clinical study of the Axl inhibitor BGB324 in combination with either the MAP kinase inhibitors trametinib (Mekinist) plus dabrafenib (Tafinlar) or the immune checkpoint inhibitor pembrolizumab (Keytruda) in patients with advanced melanoma is...
Carfilzomib May Be a Strong Candidate for Salvage Therapy in Relapsed/Refractory Multiple Myeloma—but Questions Remain
WITH THE INCLUSION of proteasome inhibitors and immunomodulatory agents first into salvage and then as components of first-line, consolidation, and maintenance regimens, response rates, depth of response, and median progression-free and overall survival have all improved for patients suffering...
Regional Radiation Therapy Reduces Risk of Regional Recurrence in Node-Positive Cutaneous Melanoma
IN A LARGE single-institution study reported in the Journal of the National Comprehensive Cancer Network, Tobin Strom, MD, and colleagues found that regional radiotherapy was associated with a reduced risk of regional recurrence in patients with node-positive cutaneous melanoma, including those...
No Progression-Free Survival Benefit With First-Line Nivolumab vs Chemotherapy in Advanced PD-L1–Positive NSCLC
AS REPORTED BY David P. Carbone, MD, PhD, of The Ohio State University Comprehensive Cancer Center, Columbus, and colleagues in The New England Journal of Medicine, the phase III CheckMate 026 trial has shown no progression-free survival benefit for first-line nivolumab (Opdivo) vs platinum-based...
For HPV Vaccine to Have Optimal Impact, ‘Provider Hesitancy’ Must Be Overcome
Honoring National Cancer Institute researchers Douglas R. Lowy, MD, and John T. Schiller, PhD, with the Lasker-DeBakey Clinical Medical Research Award for advances in technology that enabled the development of human papillomavirus (HPV) vaccines to prevent cervical cancer and other tumors caused by ...
Phase III Trial Shows No Survival Benefit to Adding First-Line Ipilimumab to Chemotherapy in Advanced Squamous NSCLC
IN A PHASE III trial reported by Ramaswamy Govindan, MD, of Washington University School of Medicine, and colleagues in the Journal of Clinical Oncology, the addition of first-line ipilimumab (Yervoy) to paclitaxel/carboplatin did not improve overall survival in patients with advanced squamous...
Nivolumab/Ipilimumab in Patients With Advanced Melanoma Who Did or Did Not Discontinue Induction Treatment due to Adverse Events
IN A RETROSPECTIVE pooled analysis of the CheckMate 069 and 067 studies reported in the Journal of Clinical Oncology, Dirk Schadendorf, MD, of the University Hospital Essen and the German Cancer Consortium, and colleagues found little difference in the efficacy of combined nivolumab (Opdivo) and...
Tremelimumab in Previously Treated Advanced Malignant Mesothelioma
In the randomized phase IIB DETERMINE trial, the cytotoxic T-lymphocyte–associated protein 4 (CTLA-4) inhibitor tremelimumab did not improve overall survival vs placebo as second- or third-line treatment of relapsed malignant mesothelioma. These findings were reported in The Lancet Oncology by...
Expert Point of View: Markus Joerger, MD, PhD, and Domenica Lorusso, MD, PhD
PRESS CONFERENCE MODERATOR Markus Joerger, MD, PhD, of St. Gallen Cancer Center, Switzerland, indicated that prior to the current study, it was unclear whether chemotherapy followed by surgery would be superior to chemoradiotherapy. “I think we all agree that it has been confirmed as the standard...
Breast Cancer Has Changed Me, But the Change Has Been Positive
I’ve always had dense breasts and avoided doing breast self-exams because I couldn’t tell if the lumpiness I was feeling was something serious or merely normal fibrous tissue. Instead I relied on my yearly mammogram to spot any early signs of cancer. Four years ago, I was once again relieved to...
CheckMate 238: Nivolumab Shows Benefit as Adjuvant Melanoma Treatment
IN THE TREATMENT of malignant melanoma, immune checkpoint inhibitors are no longer just for metastatic disease, and the best type may be agents targeting the programmed cell death protein 1 (PD-1), according to results of CheckMate 238, presented at the European Society for Medical Oncology (ESMO)...
Adjuvant BRAF/MEK Inhibition Improves Survival in Resectable Melanoma
FOR PATIENTS with locally advanced, resectable melanoma harboring BRAF mutations, adjuvant treatment with BRAF/ MEK inhibition significantly improves overall survival, results of the COMBI-AD trial have shown. The study was presented at the European Society for Medical Oncology (ESMO) 2017...
Alectinib Yields Favorable Results in Phase III Trials of ALK-Positive NSCLC
RESULTS OF TWO separate phase III trials confirm the activity of alectinib (Alecensa) in the central nervous system (CNS) in patients with anaplastic lymphoma kinase (ALK)-positive non–small cell lung cancer (NSCLC). Results lend support for alectinib as the better first-line treatment option over...
Expert Point of View: Cora Sternberg, MD
FORMAL DISCUSSANT of the STAMPEDE trial, Cora Sternberg, MD, Chief of the Department of Medical Oncology, San Camillo Forlanini Hospital, Rome, commended the study design. “This multiarm, multistage design is very innovative. The investigators plan up to 10 trials over 20 years. The first results...
ASCO Recognizes New Jersey Representative Leonard Lance With Congressional Leadership Award
ASCO HAS PRESENTED Representative Leonard Lance, of New Jersey’s 7th district, with its second annual Congressional Leadership Award in recognition of the lawmaker’s exceptional commitment to supporting cancer research and treatment. ASCO President Dr. Bruce Johnson presented the award to...
Expert Point of View: Yohann Loriot, MD, PhD
FORMAL DISCUSSANT of the RANGE trial at the ESMO 2017 Congress, Yohann Loriot, MD, PhD, of the Institut Gustave Roussy and University of Paris-Saclay, Villejuif, Paris, said that although the study met its primary endpoint, he was not sure the absolute improvement in progression-free survival is...
23 ASTRO Members Awarded Fellows Designation
The American Society for Radiation Oncology (ASTRO) has selected 23 distinguished members to receive the ASTRO Fellow designation. The 2017 class of Fellows was recognized during the Awards Ceremony at ASTRO’s 59th Annual Meeting, which was held September 24–27 in San Diego. The Fellows Program,...
Cutting Radiation Exposure by 50% Appears Safe and Effective in HPV-Positive Head and Neck Cancer
AGGRESSIVE REDUCTION in radiation therapy appears to be a potential win-win situation for patients with human papillomavirus (HPV)-associated oropharyngeal squamous cell carcinoma, according to the results of a phase II trial presented at the 2017 Annual Meeting of the American Society for...
Consolidative Radiation Therapy: New Paradigm for Limited Metastatic NSCLC?
ADDING CONSOLIDATIVE RADIATION therapy to maintenance chemotherapy had a robust effect on preventing disease progression compared with maintenance chemotherapy alone in patients with limited metastatic non–small cell lung cancer (NSCLC), according to a late-breaking study presented at the 2017...
Could the Rising Rates of Colorectal Cancer in AYAs Be Linked to HPV Infection?
TWO STUDIES published this year examining the incidence of colorectal cancer in adolescents and young adults (AYAs) show an undeniable and sobering trend: Colorectal cancer rates are increasing in this age group, and younger people are dying of the cancer at slightly higher rates than in previous...
Smashing the Glass Ceiling in Medicine
IT IS A SAD TRUTH that academic medicine, like many other professions, has a glass ceiling that hampers its ambitions. In medicine, this glass ceiling blocks women and minority faculty from reaching the highest ranks of leadership. Even if the root cause is not yet known, we want to eliminate...
Second-Line Pembrolizumab Extends Survival in Urothelial Cancer
PEMBROLIZUMAB (KEYTRUDA) extended survival by about 3 months in patients with advanced urothelial cancer whose disease progressed on platinum-based chemotherapy vs investigator’s choice of therapy, according to the mature results of the KEYNOTE-045 trial presented at the European Society for...
Survival in Patients Treated With Adjuvant Chemoradiotherapy After Resection of Gastric Cancer
In the CALGB 80101/Alliance trial, no difference in overall survival was found for adjuvant chemoradiotherapy with epirubicin, cisplatin, and fluorouracil (ECF) vs fluorouracil and leucovorin (5-FU/LV) after curative resection of gastric cancer. The findings were reported in the Journal of Clinical ...
IASLC 2017: Poziotinib Yields High Response Rates in Patients With NSCLC With EGFR Exon 20 Insertion
A targeted therapy studied at The University of Texas MD Anderson Cancer Center has produced high response rates among patients with metastatic non–small cell lung cancer (NSCLC) that carries a highly treatment-resistant mutation. Preliminary results were presented at the International...
Early Love of Science and Famous Mentor Paved the Way for Gwen L. Nichols, MD, in Hematologic Cancer
Nationally regarded leukemia and lymphoma specialist Gwen L. Nichols, MD, was born in the Bronx, New York, and when she became of school age, her parents moved to the upstate suburb of Chappaqua, where she grew up. Asked if there were any physicians in her family who might have influenced her...
Chronicling a Family’s History of Cancer
Cancer has been an intimate part of Nancy Borowick’s life since her mother, Laurel, was diagnosed with breast cancer in 1997, when Nancy was 12. She began photographing her mother’s journey with the disease after the cancer recurred in 2009 for her final project for the Documentary Photography and ...
Engaging Patients in Value-Based Care
Turning the Tide Against Cancer is an annual conference sponsored by the Personalized Medicine Coalition, American Association for Cancer Research (AACR), Feinstein Kean Healthcare, and CancerCare. Margaret Foti, PhD, MD (hc), AACR Chief Executive Officer, introduced the proceedings for the 2017...
FDA Approves CAR T-Cell Therapy to Treat Adults With Certain Types of Large B-Cell Lymphoma
On October 18, the U.S. Food and Drug Administration (FDA) approved axicabtagene ciloleucel (Yescarta), a cell-based gene therapy, to treat adult patients with certain types of large B-cell lymphoma who have not responded to or who have relapsed after at least two other kinds of treatment....
IASLC 2017: IASLC Releases New Atlas of EGFR Testing
The International Association for the Study of Lung Cancer (IASLC) released its Atlas of EGFR Testing in Lung Cancer at the IASLC 18th World Conference on Lung Cancer (WCLC) in Yokohama, Japan. The EGFR Atlas provides health-care professionals with information on EGFR testing processes and...
